Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN): review of development and future perspectives (2012)

Peer-Reviewed Study · Maehara Y, Tsujitani S, Saeki H, Oki E, Yoshinaga K, Emi Y, Morita M, Kohnoe S, Kakeji Y, Yano T, Baba H · January 2012

Maehara Y et al., 2012-01: Review of PSK's development by Japanese surgical oncologists: approved in 1976 for digestive, lung and breast cancers, in clinical use from 1977, and re-approved in 1989 for combination use in resected gastric and colorectal cancer and small-cell lung cancer.

PSK has been shown to regress tumors clinically, and was approved in 1976 for the treatment of cancers of the digestive organ, lung and breast. Clinical use in Japan was started in 1977.

Introduction (full text)

Maehara Y et al., 2012-01: Review of PSK's development by Japanese surgical oncologists: approved in 1976 for digestive, lung and breast cancers, in clinical use from 1977, and re-approved in 1989 for combination use in resected gastric and colorectal cancer and small-cell lung cancer. Study type: review.